Organon & Co 2021 SR
The report details Organon's inaugural year as a standalone women's health company following its spin-off in June 2021. It highlights the company's focus on addressing unmet medical needs for women, including contraception, fertility, and maternal health. Key achievements include reaching 140 markets, preventing 40 million unintended pregnancies through access initiatives, and maintaining a board where 69% of directors are women. The company established ambitious environmental goals, aiming for net zero greenhouse gas emissions by 2050 and a 25% reduction in Scope 1 and 2 emissions by 2025.
Company: Organon & Co
Sector: Health Care
Country: United States
Year: 2021
Type: SR
Pages: 88
Back to company
Organon & Co
ESG Report
The report details Organon's inaugural year as a standalone women's health company following its spin-off in June 2021. It highlights the company's focus on addressing unmet medical needs for women, including contraception, fertility, and maternal health. Key achievements include reaching 140 markets, preventing 40 million unintended pregnancies through access initiatives, and maintaining a board where 69% of directors are women. The company established ambitious environmental goals, aiming for net zero greenhouse gas emissions by 2050 and a 25% reduction in Scope 1 and 2 emissions by 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jun 2, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees